Sign in

Kelly Hsu

Research Analyst at Jefferies

Kelly Hsu is an analyst at Jefferies specializing in equity research, though specific details about her sector coverage, tracked company list, and performance metrics such as success rates or analyst rankings are not publicly documented. There is no available information confirming her coverage of particular companies, nor are there quantitative metrics like average returns or rankings from TipRanks or similar platforms. Her career timeline, including her start date in the finance industry, previous employers, or her tenure at Jefferies, is not disclosed in accessible sources. Likewise, her professional credentials such as FINRA registration or securities licenses, along with notable industry awards or recognitions, are not reported in publicly available data.

Kelly Hsu's questions to Verastem (VSTM) leadership

Kelly Hsu's questions to Verastem (VSTM) leadership • Q2 2025

Question

An analyst on for Kelly Hsu asked about the key performance indicators Verastem is tracking to measure the launch momentum of AvmapKefaxin Jakobak and how these should be interpreted for the second half of the year.

Answer

President and CEO Dan Paterson stated it's still early but they are beginning to track the breadth of data from specialty pharmacies, distributors, and GPOs to identify repeatable patterns. COO Matthew Ros elaborated that future reporting on performance will be anchored against their three strategic imperatives: healthcare community engagement, seamless patient access, and patient population support.

Ask Fintool Equity Research AI